Low Dose CT Scanning for Lung Cancer

Low Dose CT scanning for Lung Cancer Patrick Strouse Lynn Blazaskie M.S.,R.T.(R)(ARRT) Abstract Computed Tomography (CT) is the imaging of patients in a cross-sectional plane using x-ray. CT is used to diagnose diseases and is producing more efficient ways of this by making radiation dose lower, this leads to Low Dose CT and its abilities in diagnosing lung cancer. The research portrayed in this project provides points across the different aspects of Low Dose Computed Tomography (CT) and its relation to lung cancer to explain the growing new scan of Low Dose CT. Lung cancer is described as a cancer originating in the lungs which the cells grow exponentially causing many mortalities in the world. Lung cancer can be determined by many risk factors such as smoking, radon exposure, family history of lung cancer, and even diet. The symptoms for lung cancer may not be apparent early on, but many researchers find that detecting it early is the best chance for survival. Incorporating evidence shows that Low Dose CT is the best way to detect lung cancer early and to substantially raise the survival rate of this deadly disease, in evidence it shows the statistics of early findings on these scans as compared to others. This research also brings into consideration some of the reasons people may not have access to these scans, this is because of the newer technology and many do not know of it or its effectiveness to save lives. Some future work with these findings should raise the awareness of this scan and educate more individuals. Keywords: Lung Cancer, Low Dose CT, Computed Tomography, Healthhttps://digitalcommons.misericordia.edu/medimg_seniorposters/1041/thumbnail.jp

End points for sickle cell disease clinical trials:Patient-reported outcomes, pain, and the brain

To address the global burden of sickle cell disease (SCD) and the need for novel therapies, the American Society of Hematology partnered with the US Food and Drug Administration to engage the work of 7 panels of clinicians, investigators, and patients to develop consensus recommendations for clinical trial end points. The panels conducted their work through literature reviews, assessment of available evidence, and expert judgment focusing on end points related to: patient-reported outcomes (PROs), pain (non-PROs), the brain, end-organ considerations, biomarkers, measurement of cure, and low-resource settings. This article presents the findings and recommendations of the PROs, pain, and brain panels, as well as relevant findings and recommendations from the biomarkers panel. The panels identify end points, where there were supporting data, to use in clinical trials of SCD. In addition, the panels discuss where further research is needed to support the development and validation of additional clinical trial end points.</p